Posted by Michael Wonder on 14 Mar 2022
Imlifidase for preventing kidney transplant rejection in people with chronic kidney disease
11 March 2022 - The Department of Health and Social Care has asked NICE to produce guidance on using imlifidase in the NHS in England.
Imlifidase is not recommended for the treatment of adults who are waiting for a kidney transplant from a deceased donor, who are highly sensitised with human leukocyte antigens and have a positive crossmatch with the donor.
